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Dysregulation of mesenchymal-epithelial transition factor receptor ty-
rosine kinase pathway leads to cell proliferation, protection from apo-
ptosis, angiogenesis, invasion, and metastasis. It can be dysregulated
through overexpression, constitutive activation, gene amplification, li-
gand-dependent activation or mutation. New drugs targeting various
mesenchymal-epithelial transition factor pathways are being investi-
gated with promising results.
Key Words: MET pathway, Therapeutic target, Thoracic tumorigenesis.
(J Thorac Oncol. 2009;4: 444–447)
Many novel pathways critical to thoracic tumorigenesisare being identified and developed as potential ther-
apeutic targets. Mesenchymal-epithelial transition factor
(MET) receptor tyrosine kinase can be mutated or overex-
pressed in a number of epithelial human cancers, including
lung and mesothelioma. It is activated by its ligand hepa-
tocyte growth factor (HGF) and in malignant cells triggers
a number of intracellular signaling transduction pathways
resulting in alteration of biologic functions including me-
tastasis.1–3
In this pathway review, we will highlight the basic
biology of MET and current approaches to therapeutic tar-
geting.
MET Structure and Pathway
MET was first discovered as an oncogene that en-
codes for the tyrosine kinase receptor for HGF. The gene
for MET is located on chromosome 7q21-q31 and encodes
for a single precursor that is posttranscriptionally digested
and glycosylated, forming a 50 kDa extracellular -chain
and a transmembrane 140 kDa -chain, which are linked
by disulfide bonds. The MET -chain contains homolo-
gous domains shared with other proteins, including a
semaphorin (sema) domain, a PSI domain (in plexins,
semaphorins and integrins), four IPT repeats (in immuno-
globulins, plexins and transcription factors), a transmem-
brane domain, a juxtamembrane domain, a tyrosine kinase
(TK) domain, and a carboxy-terminal tail region.4,5
MET’s ligand has been identified as HGF which is
secreted by fibroblasts and smooth muscle cells.6 It binds
MET’s sema domain and induces MET dimerization, au-
tophosphorylation, and activation of tyrosine kinase cata-
lytic activity.7,8 Tyrosine phosphorylation of JM, TK and
tail domains respectively regulate internalization, catalytic
activity, and docking of substrates such as Gab-1, Grb2,
Shc, c-Cbl, which subsequently activate signal transducers
such as PI3Kinase, PLC-, STAT, ERK1, ERK2, and FAK
(Figure 1). Gab-1 is MET’s unique adaptor protein which
mediates numerous MET-initiated signals.9–14 Gab-1 acti-
vates both the Erk and PI3K pathways. The Erk pathway
regulates mitogenesis and the PI3K pathway regulates cell
survival through the Akt/PKB pathway. Both pathways
mediate cell adhesion, motility and invasion.15–17 Cell
migration and invasion are mediated by Ras, Crk, and
c-src/FAK, and branching morphogenesis further requires
the STAT3 and PLC- pathways.18–22 Specifically, activa-
tion of Ras-Rac1/Cdc42-PAK and Gab1-Crk-C3G-Rap1
regulates cell adhesion and cytoskeletal proteins. Down-
stream molecules involved in the regulation of MET-
induced motility and migration include cadherins, inte-
grins, focal adhesion kinase, and paxillin.23 Of note,
paxillin can be somatically mutated in lung cancer, and is
an important downstream target of MET.24 Furthermore,
MET signaling is involved in the regulation of tumor
angiogenesis, either directly, through the proangiogenic
activity of HGF that induces the formation of new vessels
and the sprouting of the preexisting ones, or indirectly,
through the regulated secretion of angiogenic factors, such
as vascular endothelial growth factor A, interleukin-8, and
thrombospondin-1.25–28
MET in Cancer
The regulation of MET can be influenced through over-
expression, constitutive kinase activation, gene amplification,
mutation, or paracrine/autocrine activation through HGF.29,30
It is previously shown that 67% of adenocarcinomas, 60%
of carcinoids, 57% of large cell carcinomas, 57% of
squamous cell carcinomas, and 25% of small cell lung
cancer (SCLCs) strongly expressed MET.31 When assess-
ing for functional activity with p-MET staining, 44% of
adenocarcinomas, 86% of large cell, 71% of squamous
cell, 40% of carcinoids, and 100% of SCLCs demonstrated
MET phosphorylation at the Y1003 c-Cbl binding site;
33% of adenocarcinomas, 57% of large cell and 50% of
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SCLCs demonstrated MET autophosphorylation at the
Y1230/1234/1235 site.31
A large number of missense mutations occur in the
JM domains which are thought to be key regulators of
receptor tyrosine kinases catalytic functions. Mutations at
R988C, T1010I, and S1058P were identified in a study of
127 lung adenocarcinoma.31 Among these JM domain
mutations, R988C and T1010I were previously found to
enhance tumorigenicity, MET/downstream molecule phos-
phorylation and cell motility in SCLC.32 Mutations in the
sema domain affect binding to HGF and those in the TK
domain constitutively activated MET protein in hereditary
papillary renal cell carcinomas.33 Besides missense muta-
tions, MET-mediated tumorigenesis could be a result of
gene amplification, leading to receptor overexpression.
More recently, MET amplification was observed in ap-
proximately 20% of lung cancer specimens with acquired
resistance to the epidermal growth factor receptor inhibi-
tors.34,35 It is shown that amplification of MET causes
gefitinib resistance by driving HER3-dependent activation
of PI3K. Conversely, inhibition of MET signaling restored
sensitivity to gefitinib.34 This observation further strength-
ens the hypothesis that MET activation contributes criti-
cally to tumor cell resistance.
Amplification of focal adhesion signaling molecules
such as paxillin has also been demonstrated in lung cancer.
Paxillin was highly expressed (compared with normal lung),
amplified (12.1%, 8 of 66) and correlated with increased
MET and epidermal growth factor receptor gene copy num-
bers, or mutated (somatic mutation rate of 9.4%, 18 of 191).24
FIGURE 1. Mesenchymal-epithelial transition factor (MET) Structure and Pathway. HGF, hepatocyte growth factor; SEMA,
Semaphorin-like; PSI, found in Plexins, Semaphorins, and Integrins; IPT, found in Ig-like regions, Plexins and Transcription fac-
tors; TM, Trans-Membrane; JM, Juxta-Membrane; TK, Intracellular Tyrosine Kinase; SOS, son of sevenless; GRB2, growth factor
receptor-bound protein 2; GAB1, GRB2-associated binding protein 1; PI3K, phosphoinositol 3 kinase; PLC, phospholipase C.
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Therapeutics
It is anticipated that targeted therapy against MET and
its pathway will lead to significant inhibition of cancer
growth and metastasis. The expression of MET protein has
been targeted at the RNA levels with small interference RNA,
microRNA, MET-specific ribozymes or at the level of protein
maturation. Suppression of MET expression by delivering
small interference RNA is a novel approach. SiRNA binds to
ribosomes in place of MET RNA, effectively silencing MET
RNA. MicroRNA is a form of single-stranded RNA that is
thought to regulate gene expression by cleaving specific
mRNA or by pairing with target mRNAs to silence their
translation.36,37 Ribozymes are RNA-based enzymes that bind
to and cleave RNA molecules in a sequence- specific manner.
MET protein expression can be targeted at the level of protein
maturation through inhibition of the heat shock protein
(HSP90) by geldanamycin or members of the anisomycin
antibiotic family.38
NK (N-terminal hairpin domain and Kringle domain)
inhibitors form a family of four variants of HGF -chain.
NK4, a variant of HGF comprising only the four-kringles of
the -chain is a promising competitor for HGF. NK4 binds to
MET without inducing receptor activation and thus behaves
as a full antagonist.39 Moreover, as a consequence of its
structural similarity to angiostatins, but independently from
its effect on MET signaling, NK4 is able to inhibit angiogen-
esis induced by vascular endothelial cell growth factor
(VEGF) and basic fibroblast growth factor.40 Similarly, the
anti-HGF antibody binds an epitope in the -chain of HGF
and prevents it from binding to MET. In preclinical studies,
this AMG102 (Amgen, Inc), a fully humanized monoclonal
anti-HGF IgG showed good pharmacokinetic and safety pro-
files in cynomolgus monkeys41 and synergism with temozo-
lomide and docetaxel in a U-87 MG (human glioblastoma
derived containing HGF/MET autocrine loop cells) xenograft
model in vivo.42 Phase I clinical trial with AMG 102 has been
completed and phase II trials are currently being designed.
Several MET inhibitors are currently under investiga-
tion. Previously, a broad-spectrum kinase inhibitor at ATP
binding site, K252a, was identified.43 Efforts to develop more
specific inhibitors have led to characterization of SU11274
and PHA665752. At nanomolar concentrations, they are both
at least 50-fold more selective for MET compared with other
receptor tyrosine kinases and strongly inhibit HGF-induced
activation of MET in cultured cells and tumorigenicity in
mouse models.25,44,45 Most recently, PF2341066, an orally
available selective competitor for MET has been shown to
inhibit tumor cell growth in vitro and in vivo.46,47
There are a number of kinase inhibitors that have
reached clinical trials.48 These include PF2341066, XL880
(Exelixis), XL184 (Exelixis), ARQ197 (ArQule Inc.),
SGX523 (SGX Pharmaceuticals), and MGCD265 (Methyl-
Gene). SGX523 had to be stopped prematurely in phase I trial
due to unexpected renal toxicity. Many of these inhibitors
also have activity against other kinases. In the future, differ-
entiation of MET inhibitors into specific kinase targets will
need to be made. Determining specific patient subsets based
on genetic profile that are more likely to respond to MET
kinase inhibitors will contribute to better clinical outcome of
these inhibitors. Lastly, as many tumors may require inhibi-
tion of more than one pathway, combinational strategies will
need to be further explored.
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